AAAyşe Nur Akınel

Ayşe Nur Akınel

*This is an algorithmically generated author record based on publicly available information.

Ayşe Nur Akınel has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pediatri Polikliniklerinde Sık Görülen Vakalar

    by Yahya Gül, Şeyhan Kutluğ, Esra Dişçi, Bahtınur Yener, Mahmut Cesur, Elif Arık, Hasan Kapaklı, Gaye İnAl, Feyat Tunç, Nergiz Kendirci, et al.

    Ömrünü eğitime ve tıp bilimine adamış, pediatri alanında kendi eğitimini tamamlayan ve hala sürdüren yazarlarımız ile iki yıldır süren çalışmalarımızın meyvesi olan kitabımız için çok mutluyuz. Yedi yaşından beri gece gündüz demeden çalışan, pediatri uzmanlığını ve yan dalını hakkıyla tamamlamak için çok emek harcayan arkadaşlar, tecrübelerini ve öğrendiklerini eğitime yeni başlayan meslektaşlarına aktarmak için bir kılavuz olacak bu kitabı hazırladık. Bu kitabın; pratisyen hekim, pediatri asistanları ve uzmanlarına klinik pratikte en sık karşılaşacakları hastalıkların tanısı, kliniği ve tedavisi konusunda hızlıca bilgilere ulaşabilmeleri açısından çok büyük kolaylık sağlayacağına inanıyoruz. Bu nedenle acillerde, polikliniklerde ve servislerde sıkça başvurulan bir kitap olacağını düşünüyoruz.

  • Open Access

    Multidisciplinary Management of Pediatric Hepatoblastoma: A 20-Year Single-Center Experience

    by Funda Tayfun Küpesiz, Ayşe Nur Akınel, Hilal Akbaş, Çiğdem Sivrice, Gülen Tüysüz Kintrup, Güngör Karagüzel, Mustafa Melikoğlu, Mustafa Tekinalp Gelen, Bülent Aydınlı, Alphan Küpesiz, et al.

    Background: Hepatoblastoma is rare cancer that responds well to risk-based chemotherapy, and surgical treatment is needed to achieve complete remission and satisfactory survival rates in hepatoblastoma patients. In this study, we evaluated the clinical features and treatment outcomes of pediatric hepatoblastoma patients treated in our clinic. Methods: Eighteen patients with hepatoblastoma who were treated and followed up in our center between June 1999 and June 2020 were analyzed retrospectively. All patients were evaluated by a multidisciplinary team and managed using a risk-based protocol (SIOPEL-1 and SIOPEL-3). Results: The patients’ mean age at diagnosis was 38.33 ± 52.34 months. Sixteen patients (89%) received neoadjuvant chemotherapy, and 2 patients (11%) who underwent complete mass excision at diagnosis received adjuvant chemotherapy. After neoadjuvant therapy, the tumor was completely resected in 8 patients (45%), while liver transplantation was performed in 6 patients (34%) because complete resection of the tumor was not possible. Two patients died before surgical treatment. One patient relapsed with lung metastasis after salvage chemotherapy. She is alive without disease at 64 months. The mean follow-up time was 59.3 ± 49.8 months; 5-year overall and disease-free survival rates were 88.9% and 80.8%, respectively. The 5-year overall survival rate was 100% for both liver transplant and resected patients, whereas 5-year disease-free survival was lower in transplant patients (75% vs 100%, P < .001). Conclusion: Multidisciplinary follow-up is especially important for patients who may need liver transplantation. Some patients may benefit from new treatment options such as radiofrequency ablation and cyberknife treatment. Cite this article as: Tayfun Küpesiz F, Akınel AN, Akbaş H, et al. Multidisciplinary management of pediatric hepatoblastoma: A 20-year single-center experience. Turk J Gastroenterol. 2022;33(12):1069-1078.


  • Open Access

    Clinical Characteristics and Treatment Outcomes of Patients with Malignant Extracranial Germ Cell Tumors: A 20-Year Single-Center Experience

    by Funda Tayfun Küpesiz, Gülen Tüysüz, Ayşe Nur Akınel, Ayşegül Tekneci, Ayşe Çiğdem Sivrice, Mustafa Melikoglu, Hadice Elif Pestereli, Osman Alphan Küpesiz, Elif Güler